ReviewBioMed research international2014
CXC and CC chemokines as angiogenic modulators in nonhaematological tumors.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 64 citations in OpenAlex.
- EPB41L family serves as a prognostic biomarker for kidney renal clear cell carcinoma.Cell adhesion & migration · 2026Article
- MAGI3 inhibits renal clear cell carcinoma progression through the JAK-STAT3 pathway.Translational andrology and urology · 2026Article
- Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer.Medicina (Kaunas, Lithuania) · 2025Review
- Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreatic cancer: a retrospective analysis.Frontiers in immunology · 2025Article
- The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.International journal of molecular sciences · 2024Review
- Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences.Cancers · 2023Article
- CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma.Therapeutic advances in medical oncology · 2023Article
- Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer.Journal of clinical medicine · 2022Article
- Review
- Review
- Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution.Journal of clinical medicine · 2021Article
- (Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder.Cancers · 2021Article
- Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment.Cancer cell international · 2021Article
- The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?International journal of molecular sciences · 2021Review
- Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.International journal of molecular sciences · 2021Review
- Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.Pharmacology & therapeutics · 2021Review
- Article
- Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.Breast cancer (Tokyo, Japan) · 2021Review
- Identification and Comprehensive Prognostic Analysis of a Novel Chemokine-Related lncRNA Signature and Immune Landscape in Gastric Cancer.Frontiers in cell and developmental biology · 2021Article
- Role of platelets and breast cancer stem cells in metastasis.World journal of stem cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines are a superfamily of structurally homologous heparin-binding proteins that includes potent inducers and inhibitors of angiogenesis. The imbalance between angiogenic and angiostatic chemokine activities can lead to abnormalities, such as chronic inflammation, dysplastic transformation, and even tumor development and spreading. In this review, we summarize the current literature regarding the role of chemokines as modulators of tumor angiogenesis and their potential role as therapeutic targets in patients with nonhaematological tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.